Using bacterial biomarkers to identify early indicators of cystic fibrosis pulmonary exacerbation onset - Wikidata - thesis-toulmin - TriplyDB

Using bacterial biomarkers to identify early indicators of cystic fibrosis pulmonary exacerbation onset

Using bacterial biomarkers to identify early indicators of cystic fibrosis pulmonary exacerbation onset

http://www.wikidata.org/entity/Q35143420

about

Analysis of changes in diversity and abundance of the microbial community in a cystic fibrosis patient over a multiyear period Serum Iron Level Is Associated with Time to Antibiotics in Cystic Fibrosis Metabolomics of pulmonary exacerbations reveals the personalized nature of cystic fibrosis disease.Novel outcome measures for clinical trials in cystic fibrosis Management of pulmonary exacerbations in cystic fibrosis: still an unmet medical need in clinical practice.Early pulmonary disease manifestations in cystic fibrosis mice.Niche partitioning of a pathogenic microbiome driven by chemical gradients Testing the neutral theory of biodiversity with the microbiome dataset from cystic fibrosis patients

P2860

Q34916610-7B2713D8-4E39-4B9B-9098-C145FB6B0EFA Q36437025-6D478EC3-34B7-45EC-A998-D0872F9C986F Q37191286-5DEA09F9-6799-4D6A-AB14-ECBF3066E89E Q38340406-04FF9AE4-97D9-428A-AEAF-7F14EA5071B6 Q38360133-CB17E07F-A2B5-4D4D-BA40-568D73B48C8A Q40657308-87EB8E49-4D4A-49CD-81C1-ED90D288A0FE Q58376391-CD78B872-137C-4C46-8F9B-47F5BBB682A1 Q58739509-2A80097D-E2B0-4108-8FC5-EE461050AC86

P2860

Using bacterial biomarkers to identify early indicators of cystic fibrosis pulmonary exacerbation onset

http://www.wikidata.org/entity/Q35143420

description

2011 nî lūn-bûn

@nan

2011 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի մարտին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Using bacterial biomarkers to ...... s pulmonary exacerbation onset

@ast

Using bacterial biomarkers to ...... s pulmonary exacerbation onset

@en

type

label

Using bacterial biomarkers to ...... s pulmonary exacerbation onset

@ast

Using bacterial biomarkers to ...... s pulmonary exacerbation onset

@en

prefLabel

Using bacterial biomarkers to ...... s pulmonary exacerbation onset

@ast

Using bacterial biomarkers to ...... s pulmonary exacerbation onset

@en

P1433

Q35143420-D8A6BBD1-ED02-4B91-9C32-8E3C7AEE5976

P1476

Q35143420-D489404F-095B-437F-9FC0-8013E5AC6B87

P2093

Q35143420-836876CA-EC5B-40D3-8B55-11DC9B391F0E

Q35143420-A556F024-139C-47C4-9E9F-B81AC3FC6E0B

Q35143420-D7EE9249-D15F-404C-A87F-0B6A3101A72C

Q35143420-E5DE82A4-45F1-46F5-9BEA-87AE32795C28

Q35143420-FE6BC341-5A5E-4F45-86B4-BB9A3F232EF3

P2860

Q35143420-022113F5-56C9-4CE3-AEA1-99B4177F6888

Q35143420-02CA9581-573C-4B03-95C8-67BF69C8B451

Q35143420-063409D9-AC05-4D4A-850D-0E743A02F251

Q35143420-06BB79AF-9CE2-4C28-B287-D0F5EBE831BD

Q35143420-088BE061-7AB5-4656-B52A-75090A04B10B

Q35143420-08F221E0-B678-46D7-89C4-25DCE71B8FDD

Q35143420-0C7C9440-2A14-4254-86B1-57A16DEFC620

Q35143420-0D22A220-EE25-4A0D-A9A3-76B80FE6F634

Q35143420-0DD2BDDE-76F0-4DD9-9BF4-14E1575E0D68

Q35143420-0EFA0AE8-ABB4-4AA6-98D4-99F56A790B99

P304

Q35143420-B5B9415C-3B6B-4B0A-8033-D111A5B096E9

P31

Q35143420-D313B544-D93E-40EC-8E59-09985EB7F85C

P356

Q35143420-B2ED57B3-B60F-44C7-8CBD-A5702FCCA761

P433

Q35143420-FB0E946C-121B-45BD-AF2E-A074392DD15F

P478

Q35143420-4B0B297C-74B6-4B8E-A07A-5E6A8A4E966B

P50

Q35143420-55C530C2-2F49-42AE-A51E-F06AE4E0C805

Q35143420-B220B284-7AE2-4B35-9C8F-0217E8B52C75

P577

Q35143420-B04DDA77-A69D-40A5-8AA0-E146D57002E8

P5875

Q35143420-B0334EBC-5293-4958-AC51-D3555C31E845

P698

Q35143420-4197F57C-7E80-43EF-9294-52D2CB549B1E

P921

Q35143420-417F33FA-A41B-4D7D-9173-2EC5970DDB84

Q35143420-B9BA9E8E-B07C-4FBB-B9C1-51890957985A

P932

Q35143420-C0A3838B-CBEB-45F9-9819-F3EC95D48EF4

P356

P1433

Expert Review of Molecular Diagnostics: new diagnostic technologies are set to revolutionise healthcare

P1476

Using bacterial biomarkers to ...... s pulmonary exacerbation onset

@en

P2093

Kenneth D Bruce

http://www.w3.org/2001/XMLSchema#string

Lucas R Hoffman

http://www.w3.org/2001/XMLSchema#string

Mary P Carroll

http://www.w3.org/2001/XMLSchema#string

Matt W Johnson

http://www.w3.org/2001/XMLSchema#string

Nicole Mayer-Hamblett

http://www.w3.org/2001/XMLSchema#string

P2860

A component of innate immunity prevents bacterial biofilm development

Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum

A polymicrobial perspective of pulmonary infections exposes an enigmatic pathogen in cystic fibrosis patients

Real-time PCR in clinical microbiology: applications for routine laboratory testing.

Biomarkers and surrogate endpoints: preferred definitions and conceptual framework

Sputum induction as a research tool for sampling the airways of subjects with cystic fibrosis

Predictive 5-year survivorship model of cystic fibrosis.

Determining cystic fibrosis-affected lung microbiology: comparison of spontaneous and serially induced sputum samples by use of terminal restriction fragment length polymorphism profiling.

Biomarkers for cystic fibrosis lung disease: application of SELDI-TOF mass spectrometry to BAL fluid.

Sputum proteomics in inflammatory and suppurative respiratory diseases

P304

197-206

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/ERM.10.117

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P50

Geraint B Rogers

Jürgen Schwarze

P577

2011-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

50398028

http://www.w3.org/2001/XMLSchema#string

P698

21405970

http://www.w3.org/2001/XMLSchema#string

P921

cystic fibrosis

P932

3148893

http://www.w3.org/2001/XMLSchema#string